Vera Therapeutics, Inc. (VERA)
| Market Cap | 2.15B +9.2% |
| Revenue (ttm) | n/a |
| Net Income | -401.90M |
| EPS | -5.89 |
| Shares Out | 72.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,705 |
| Open | n/a |
| Previous Close | 29.73 |
| Day's Range | n/a |
| 52-Week Range | 23.05 - 56.05 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 77.50 (+160.07%) |
| Est. Earnings | Nov 4, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $77.5, which is an increase of 160.07% from the latest price.
News
Vera Therapeutics price target lowered to $60 from $66 at BofA
BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $60 from $66 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview…
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensati...
Vera Therapeutics announces ORIGIN 3 final efficacy analysis of Trutakna
Vera Therapeutics (VERA) announced that there will be multiple presentations at the American Society of Nephrology, ASN, Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final…
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
Vera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Final phase III data showed TRUTAKNA significantly slowed kidney function decline and reduced risk of hard outcomes in IgAN, supporting a strong U.S. launch with over 350 patient starts in 10 weeks. The company is expanding globally, pursuing new indications, and maintains a robust financial position.
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (...
Vera Therapeutics ORIGIN 3 study results positive, says Raymond James
After Vera Therapeutics (VERA) reported the final efficacy analysis for their pivotal ORIGIN 3 study needed for full approval of Trutakna in IgAN, Raymond James analyst Ryan Deschner called the…
Morning Movers: Vera Therapeutics surges after reporting IgAN study data
Stock futures are pointing to another lower open as investors brace for the Federal Reserve to begin its two-day policy meeting, with the central bank widely expected to raise interest…
Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data
07:05 EDT Vera Therapeutics (VERA) up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data
Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial
Vera Therapeutics (VERA) announced that trutakna met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy, or IgAN, at risk…
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis
Vera Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Trutakna achieved accelerated approval and commercial launch, demonstrating strong efficacy in IgA nephropathy with a favorable safety profile and broad label. Early launch metrics are positive, with robust payer support and a well-prepared sales force targeting a large market.
Vera Therapeutics price target raised to $83 from $76 at JPMorgan
JPMorgan raised the firm’s price target on Vera Therapeutics (VERA) to $83 from $76 and keeps an Overweight rating on the shares. The firm updated the company’s model ahead of…
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will present a...
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Fervo Energy ($FRVO), Vera Therapeutics ($VERA), and Hut 8 ($HUT). While each stock carries risk, analysts believe all three have more…
Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $90 from $125 and keeps a Buy rating on the shares. The firm reduced peak revenue projections for…
Vera Therapeutics price target raised to $84 from $78 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Vera Therapeutics (VERA) to $84 from $78 and keeps a Strong Buy rating on the shares. Vera’s Trutakna launch…
Vera Therapeutics price target lowered to $34 from $43 at Wedbush
Wedbush lowered the firm’s price target on Vera Therapeutics (VERA) to $34 from $43 and keeps a Neutral rating on the shares. With Trutakna launching in July, the firm sees…
Vera Therapeutics price target lowered to $66 from $70 at BofA
BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $66 from $70 and keeps a Buy rating on the shares. The firm updated its model for Q2, decreased…
Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)
“The accelerated approval and commercial launch of TRUTAKNA represent transformative milestones for Vera Therapeutics (VERA) and are the result of years of hard work and dedication. We are extremely g...
Vera Therapeutics Earnings release: Q2 2026
Vera Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Vera Therapeutics Quarterly report: Q2 2026
Vera Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
Vera Therapeutics (VERA) announced a planned transition of the chief regulatory officer position. William Turner, current chief regulatory officer of Vera Therapeutics, is planning to retire and trans...
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Offic...